STOCKHOLM, Feb. 7, 2024 /PRNewswire/ -- Moberg Pharma ABs (OMX: MOB) marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals - has now launched sales of MOB-015 under the Terclara® brand. The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.

斯德哥尔摩，2024年2月7日/PRNewswire/--瑞典的Moberg Pharma ABs（OMX:MOB）marker合作伙伴-专门销售非处方（OTC）药品的Allderma AB公司-现已推出Terclara®品牌的MOB-015销售。药店的兴趣对于Moberg Pharma对抗指甲真菌的药物具有重要意义。

.

.

' t is incredibly rewarding to work with such a committed market partner as Allderma', says Anna Ljung, CEO of Moberg Pharma, and continues:' The introduction of Terclara® to Swedish pharmacy chains has gone very well. Allderma's approach and good results demonstrate why they are an excellent partner in our home market.' Allderma is managed by the commercial leaders which were responsible for the successful Nordic launch of Nalox®, Moberg Pharma's first-generation nail fungus product..

Moberg Pharma首席执行官安娜·荣格（AnnaLjung）说：“与Allderma这样一个坚定的市场合作伙伴合作，是一件令人难以置信的收获。”她继续说道：“Terclara®在瑞典连锁药店的引入非常成功。Allderma的方法和良好的结果证明了为什么他们是我们国内市场的优秀合作伙伴。”Allderma由商业领袖管理，他们负责在北欧成功推出Nalox®，这是Moberg Pharma的第一代指甲真菌产品。。

'We have high expectations for the launch of MOB-015 - the first topical medication with an equivalent antifungal effect to tablets but without the risk of serious side effects. The goal is the same as last time, to achieve a market-leading position', says Mimmi Frölén, CEO of Allderma AB.

“我们对MOB-015的推出抱有很高的期望，MOB-015是第一种与片剂具有同等抗真菌作用但没有严重副作用风险的局部用药。Allderma AB首席执行官米米·弗罗伦（MimmiFrölén）表示，目标与上次一样，是取得市场领先地位。

Currently, the majority of pharmacies throughout Sweden have decided to start selling Terclara®.

目前，瑞典大多数药店已决定开始销售Terclara®。

For additional information, please contact:Anna Ljung, CEO, telephone: +46 707 66 60 30, E-mail: [email protected]Anders Bröijersén, Chief Medical Officer, telephone: +46 760 01 15 76, E-mail: [email protected]

如需更多信息，请联系：首席执行官Anna Ljung，电话：+46 707 66 60 30，电子邮件：[受电子邮件保护]首席医疗官Anders Bröijersén，电话：+46 760 01 15 76，电子邮件：[受电子邮件保护]

About this informationThis information was submitted for publication, through the agency of the contact persons set out above, on February 7th, 2024, at 8.00 am CEST.

关于此信息，此信息已于2024年2月7日上午8:00通过上述联系人机构提交出版。

About MOB-015 and Onychomycosis Approximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The global market opportunity is significant with more than hundred million patients worldwide and a clear demand for better products. Moberg Pharma estimates the annual worldwide peak sales potential for MOB-015 to be in the range of USD 250-500 million..

关于MOB-015和甲真菌病大约10%的普通人群患有甲真菌病，大多数患者未经治疗。全球市场机会巨大，全球有一亿多患者，对更好的产品有明确的需求。Moberg Pharma估计，MOB-015的年度全球峰值销售潜力在2.5亿至5亿美元之间。。

MOB-015 is an in-house developed topical formulation of terbinafine, enabling effective concentrations of terbinafine to the nail and nail bed while avoiding the risk of systemic exposure seen with oral terbinafine use. Oral terbinafine is currently the gold standard for treating onychomycosis but associated with safety issues, including drug interactions and liver damage.

MOB-015是一种内部开发的特比萘芬局部制剂，可使特比萘芬有效浓度到达指甲和甲床，同时避免口服特比萘芬引起全身暴露的风险。口服特比萘芬目前是治疗甲真菌病的金标准，但与安全问题有关，包括药物相互作用和肝损伤。

MOB-015 is recommended for national approval in 13 European countries and is launched in Sweden under the brand name Terclara®. The approval is supported by two Phase 3 trials where MOB-015 demonstrated superior levels of mycological cure (76% vs up to 42% for comparators), and a significantly better complete cure rate compared to vehicle, without any serious adverse reactions..

MOB-015建议在13个欧洲国家获得国家批准，并在瑞典以Terclara®品牌推出。该批准得到了两项3期临床试验的支持，其中MOB-015表现出较高的真菌学治愈率（76%比对照组高达42%），与载体相比，完全治愈率明显提高，没有任何严重的不良反应。。

About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company's asset, MOB-015, is a novel topical treatment for onychomycosis, for which market approvals in several EU-countries has recently been obtained.

关于Moberg Pharma，www.mobergpharma.com Moberg Pharma AB（publ）是一家瑞典制药公司，专注于基于已证实化合物的药物输送将专有创新商业化。该公司的资产MOB-015是一种治疗甲真菌病的新型局部治疗方法，最近已在多个欧盟国家获得市场批准。

Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the Company's shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB)..

来自800多名MOB-015患者的3期临床试验数据表明，该产品有可能成为甲真菌病的未来市场领导者。Moberg Pharma与包括欧洲和加拿大在内的多个地区的商业合作伙伴签订了协议。莫贝格制药（Moberg Pharma）总部位于斯德哥尔摩，公司股票在纳斯达克斯德哥尔摩（Nasdaq Stockholm）的小盘股名单上上市。。

About Allderma Pharmaceuticals, www.allderma.se Allderma Pharmaceuticals is a Swedish pharmaceutical company that since 2001 develops, sells and markets over the counter and self-care products. The range spans a number of different treatment areas, with a focus and expertise in dermatology. Founder Hans Svartholm started Allderma after working in the pharmaceutical industry for many years.

关于Allderma Pharmaceuticals，www.Allderma.se Allderma Pharmaceuticals是一家瑞典制药公司，自2001年以来开发，销售和销售非处方药和自我护理产品。该范围涵盖了许多不同的治疗领域，重点是皮肤病学和专业知识。创始人汉斯·斯瓦瑟姆（HansSvartholm）在制药行业工作多年后创办了Allderma。

The idea was simple and still applies it should be easy to find an effective and safe product for the most common skin problems. Allderma emphasis and invests in information for healthcare providers, pharmacists, doctors and consumers. Product specialists work continuously to be a spear head in research and innovation within dermatology.

这个想法很简单，仍然适用。应该很容易找到一种有效且安全的产品来治疗最常见的皮肤问题。Allderma重视并投资于医疗保健提供者、药剂师、医生和消费者的信息。产品专家不断努力成为皮肤病学研究和创新的先锋。

Allderma has been part of 3iM Invest AB's investment area Consumer Healthcare since 2020..

自2020年以来，Allderma一直是3iM Invest AB投资领域消费者医疗保健的一部分。。

The following files are available for download:

以下文件可供下载：

https://mb.cision.com/Main/1662/3923400/2586205.pdf

https://mb.cision.com/Main/1662/3923400/2586205.pdf

MOB-015 is launched in Sweden under the brand name Terclaraâ€' pharmacies report major demand for the new medication

MOB-015在瑞典推出，品牌为Terclara，药店报告对这种新药的主要需求

SOURCE Moberg Pharma

来源：Moberg Pharma